Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Advances and challenges on the in vitro production of secondary metabolites from medicinal plants

Texto completo
Cardoso, Jean Carlos [1] ; de Oliveira, Maria Eduarda B. S. [1] ; Cardoso, I, Fernanda de C.
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] I, Univ Fed Sao Carlos UFSCar, Araras, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: Horticultura Brasileira; v. 37, n. 2, p. 124-132, APR-JUN 2019.
Citações Web of Science: 0

The production of secondary metabolites from medicinal plants, also called Plant-Derived Medicinal Compounds (PDMC), is gaining ground in the last decade. Concomitant to the increase in the knowledge about pharmacological properties of these compounds, horticultural plants are becoming the most important, sustainable and low-cost biomass source to obtain high-complex PDMCs to be used as medicaments. Biotechnological tools, including plant cell and tissue culture and plant genetic transformation, are increasingly being employed to produce high quality and rare PDMC under in vitro conditions. The proper use of these technologies requires studies in organogenesis to allow for better control of in vitro plant development and, thus, to the production of specific tissues and activation of biochemical routes that result in the biosynthesis of the target PDMCs. Either biotic or abiotic factors, called elicitors, are responsible for triggering the PDMC synthesis. In vitro techniques, when compared to the conventional cultivation of medicinal plants in greenhouse or in the field, have the advantages of (1) producing PDMCs in sterile and controlled environmental conditions, allowing better control of the developmental processes, such as organogenesis, and (2) producing tissues with high PDMC contents, due to the efficient use of different biotic and abiotic elicitors. Nevertheless, the process has many challenges, e.g., the establishment of step-by-step protocols for in vitro biomass and PDMC production, both involving and being affected by many factors. Other limitations are the high costs in opposition to the relatively cheaper alternative of growing medicinal plants conventionally. This paper aims to quickly review the general origin of plant secondary metabolites, the leading techniques and recent advances for PDMC in vitro production, and the challenges around the use of this promising technology. (AU)

Processo FAPESP: 19/00243-7 - Calogênese in vitro como alternativa a produção de filantina e hipofilantina em Phyllantus amarus
Beneficiário:Maria Eduarda Barboza Souza de Oliveira
Linha de fomento: Bolsas no Brasil - Iniciação Científica